Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
33.22
-0.39 (-1.16%)
At close: Mar 20, 2026, 4:00 PM EDT
33.38
+0.16 (0.48%)
After-hours: Mar 20, 2026, 7:26 PM EDT

Soleno Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
190.41----
Cost of Revenue
2.7----
Gross Profit
187.71----
Selling, General & Admin
132.13105.8613.489.8410.81
Research & Development
40.6378.5725.1915.2721.45
Other Operating Expenses
5.543.242.71-0.71-0.73
Total Operating Expenses
178.29187.6741.3824.431.53
Operating Income
9.41-187.67-41.38-24.4-31.53
Interest Income
16.9512.052.580.30.11
Interest Expense
-5.48-0.23---
Other Non-Operating Income (Expense)
---0.180.030.51
Total Non-Operating Income (Expense)
11.4811.822.40.330.62
Pretax Income
20.89-175.85-38.99-24.07-30.91
Net Income
41.37-351.7-77.98-24.07-30.91
Net Income Attributable to Preferred Dividends
0.42----
Net Income to Common
41.37-351.7-77.98-24.07-30.91
Shares Outstanding (Basic)
51401685
Shares Outstanding (Diluted)
52401685
Shares Change (YoY)
30.39%143.61%96.40%57.90%27.39%
EPS (Basic)
0.40-4.38-2.36-2.87-5.81
EPS (Diluted)
0.39-4.38-2.36-2.87-5.81
Free Cash Flow
46.73-69.31-24.94-20.79-27.79
Free Cash Flow Per Share
0.89-1.73-1.51-2.48-5.23
Gross Margin
98.58%----
Operating Margin
4.94%----
Profit Margin
10.97%----
FCF Margin
24.54%----
EBITDA
11.43-185.68-39.43-22.43-29.57
EBITDA Margin
6.00%----
EBIT
9.41-187.67-41.38-24.4-31.53
EBIT Margin
4.94%----
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q